================================================================================
CLINICAL TRIALS MATCHES REPORT (STUDIES WITH PUBLICATIONS AND POSTED RESULTS ONLY)
================================================================================

Patient ID: 3
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 DOTATOC PET: geringe Speicherung der Leberläsionen.
07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Clinical Question: Weitere Therapie, Everolimus oder PRRT?
Report generated: 2025-07-17 16:16:37

Found 10 relevant clinical trials (with publications and posted results)
--------------------------------------------------------------------------------

1. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
   NCT ID: NCT03375320
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study appears clinically relevant for the patient. The study explicitly includes patients with neuroendocrine tumors (NET), specifically both pancreatic and non-pancreatic (carcinoid) origin, and the patient has a well-differentiated NET of the small intestine with liver metastases. While the patient's ECOG and age are unknown, the inclusion criteria do not immediately exclude them based on the available information. The study investigates cabozantinib, which could be a viable alternative to everolimus or PRRT, addressing the clinical question. Finally, the study has published results in a peer-reviewed journal, indicating good scientific quality.
   Has Posted Results: YES (verified)
   Condition: Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm
   Intervention: Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2018-10-26
   Completion Date: 2025-11-22
   Locations: Katmai Oncology Group, Anchorage, United States; Kingman Regional Medical Center, Kingman, United States; Mayo Clinic Hospital in Arizona, Phoenix, United States
   URL: https://clinicaltrials.gov/study/NCT03375320
   Summary: This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherap...
   Publications Found: 1
     1. Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of ag...
        PMID: 33152282
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/33152282/
----------------------------------------

2. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
   NCT ID: NCT01578239
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study is clinically relevant for the patient. The study focuses on midgut carcinoid tumors, which aligns with the patient's diagnosis of a small intestinal NET. The patient's history of surgery and current consideration of Everolimus or PRRT suggests they are seeking further treatment for progressive disease, fitting the study's inclusion criteria of progressive disease on Octreotide LAR. While the patient's ECOG and biomarker data are missing, the study's criteria regarding KPS (>=60) and Ki67 (<=20%) would need to be met for eligibility. The study is a Phase 3 trial with published results, indicating good scientific quality and a potentially useful alternative treatment option (PRRT with 177Lu-DOTA0-Tyr3-Octreotate) to Everolimus.
   Has Posted Results: YES (verified)
   Condition: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
   Intervention: Octreotide LAR; 177Lu-DOTA0-Tyr3-Octreotate
   Sponsor: Advanced Accelerator Applications
   Start Date: 2012-09-06
   Completion Date: 2021-01-18
   Locations: Cedars-Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles, United States; Stanford Cancer Center, Palo Alto, United States; Moffitt Cancer Center, Tampa, United States
   URL: https://clinicaltrials.gov/study/NCT01578239
   Summary: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, in...
   Publications Found: 4
     1. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E,...
        PMID: 34793718
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/34793718/
     2. Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M...
        PMID: 32123969
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/32123969/
     3. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, ...
        PMID: 29878866
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/29878866/
----------------------------------------

3. A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
   NCT ID: NCT03070301
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study appears clinically relevant for the patient. The study focuses on advanced neuroendocrine tumors, which aligns with the patient's diagnosis of a duodenal NET with metastases. The inclusion criteria of Ki67 ≤ 30% and foregut origin (duodenal) are potentially met, although Ki67 is not specified in the patient data. The study investigates Everolimus, which is a treatment option being considered for the patient. While the patient's ECOG and age are unknown, the study requires ECOG 0 or 1, and the patient's prior therapies are not specified, the exclusion criteria regarding prior mTOR inhibitors would need to be confirmed. The study is Phase 2, completed, and has published results, indicating good scientific quality.
   Has Posted Results: YES (verified)
   Condition: Neuroendocrine Tumors
   Intervention: LEE011; everolimus
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2017-02-27
   Completion Date: 2024-01-31
   Locations: Massachusetts General Hospital, Boston, United States; Dana Farber Cancer Institute, Boston, United States; Beth Israel Deaconess Medical Center, Boston, United States
   URL: https://clinicaltrials.gov/study/NCT03070301
   Summary: The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
   Publications Found: 1
     1. Raj N, Zheng Y, Hauser H, Chou J, Rafailov J, Bou-Ayache J, Sawan P, Chaft J, Ch...
        PMID: 33640871
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/33640871/
----------------------------------------

4. Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
   NCT ID: NCT01970540
   Status: COMPLETED
   Phase: PHASE1
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study is clinically relevant for the patient. The inclusion criteria explicitly list 'Gastroenteropancreatic neuroendocrine tumors' which directly matches the patient's diagnosis of a neuroendocrine tumor of the small intestine. The patient's age is likely within the 18-75 range, and assuming a reasonable ECOG performance status (≤1), they would likely meet the inclusion criteria. The combination of lurbinectedin and doxorubicin represents a potential alternative treatment option to consider alongside Everolimus or PRRT, and the study has published results, indicating a level of scientific rigor.
   Has Posted Results: YES (verified)
   Condition: Endometrial Adenocarcinomas; Neuroendocrine Tumors; Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
   Intervention: lurbinectedin (PM01183); Doxorubicin
   Sponsor: PharmaMar
   Start Date: 2011-05-25
   Completion Date: 2017-08-09
   Locations: Hospital Universitari Vall D'Hebron, Barcelona, Spain; Centro Oncológico Md Anderson International España, Madrid, Spain; Hospital Ramón Y Cajal, Madrid, Spain
   URL: https://clinicaltrials.gov/study/NCT01970540
   Summary: Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with doxo...
   Publications Found: 1
     1. Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de M...
        PMID: 33704620
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/33704620/
----------------------------------------

5. A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
   NCT ID: NCT02875223
   Status: TERMINATED
   Phase: PHASE1
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study appears clinically relevant for the patient. The study specifically enriches for grade 2 NETs, which matches the patient's diagnosis of a G2 NET of the small intestine. The inclusion criteria of advanced/unresectable tumors aligns with the patient’s metastatic disease. While the patient’s ECOG status and age are unknown, the study requires ECOG 0-1, which is a reasonable assumption. The intervention, CC-90011, represents a novel therapy option to consider alongside Everolimus or PRRT. Finally, the study has published results in peer-reviewed journals, indicating good scientific quality.
   Has Posted Results: YES (verified)
   Condition: Lymphoma, Non-Hodgkin; Neoplasms
   Intervention: CC-90011; Rifampicin; Itraconazole
   Sponsor: Celgene
   Start Date: 2016-08-31
   Completion Date: 2024-03-25
   Locations: Local Institution - 101, Dijon, France; Local Institution - 102, Marseille Cedex 9, France; Local Institution - 100, Villejuif Cedex, France
   URL: https://clinicaltrials.gov/study/NCT02875223
   Summary: Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and NECs) and R/R NHL (MZL, including extranodal MZL \[EMZL\], splenic MZL \[SM...
   Publications Found: 2
     1. Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, Curigl...
        PMID: 33046517
        Type: BACKGROUND
        Link: https://pubmed.ncbi.nlm.nih.gov/33046517/
     2. Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, More...
        PMID: 35737639
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/35737639/
----------------------------------------

6. Study of Everolimus (RAD001) in Combination With Lenalidomide
   NCT ID: NCT01218555
   Status: COMPLETED
   Phase: PHASE1
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study is clinically relevant for the patient. The study investigates everolimus, one of the treatment options the physician is considering. While the study population is broad (advanced refractory solid malignancies), the inclusion criteria do not explicitly exclude NET patients and the patient's advanced disease with liver metastases fits the study's target population. Assuming the patient meets the unspecified ECOG, age, and lab value criteria, they would likely be eligible. The study has published results, indicating a level of scientific rigor and potential benefit, making it a potentially useful source of information for treatment decisions.
   Has Posted Results: YES (verified)
   Condition: Solid Organ Malignancies; Adenoidcystic Carcinoma; Neuroendocrine Tumors
   Intervention: Lenalidomide; Everolimus
   Sponsor: Emory University
   Start Date: 2010-09-09
   Completion Date: 2020-11-05
   Locations: Grady Health System, Atlanta, United States; Emory University Winship Cancer Institute, Atlanta, United States
   URL: https://clinicaltrials.gov/study/NCT01218555
   Summary: The purpose of this study is to study the combination of two anticancer drugs, everolimus (RAD001) and lenalidomide in patients whose cancer is no longer responding to standard treatment or patients who are unable to tolerate the standard treatment for their cancer.
   Publications Found: 1
     1. Harvey RD, Carthon BC, Lewis C, Hossain MS, Zhang C, Chen Z, Harris WB, Alese OB...
        PMID: 32704173
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/32704173/
----------------------------------------

7. Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
   NCT ID: NCT01782443
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study appears clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, and the patient has a G2 NET of the small intestine with liver metastases. The inclusion criteria do not explicitly exclude the patient based on the provided information; no age, ECOG, or specific biomarker contraindications are mentioned. The intervention, Ziv-aflibercept, represents a potentially useful alternative or addition to current treatment options like Everolimus or PRRT being considered for the patient. Finally, the study is completed, has published results, and is a peer-reviewed publication, indicating good scientific quality.
   Has Posted Results: YES (verified)
   Condition: Carcinoid Tumor
   Intervention: Ziv-aflibercept
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2013-02-13
   Completion Date: 2021-12-26
   Locations: Massachusetts General Hospital, Boston, United States; Brigham and Women's Hospital, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
   URL: https://clinicaltrials.gov/study/NCT01782443
   Summary: This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug, Ziv-aflibercept, is being studied. It also means that the FDA has not yet approv...
   Publications Found: 1
     1. Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger ...
        PMID: 36395401
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/36395401/
----------------------------------------

8. Phase 2 Study of ONC201 in Neuroendocrine Tumors
   NCT ID: NCT03034200
   Status: COMPLETED
   Phase: PHASE2
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study appears clinically relevant for the patient. The study explicitly includes neuroendocrine tumors, and the patient has a well-defined small intestinal NET with liver metastases. The inclusion criteria do not immediately rule the patient out – there’s no age limit specified that would exclude them, prior therapy number is unlimited, and basic organ function requirements are standard. While the patient's ECOG is unknown, the study requires a Karnofsky score ≥60%, which is a reasonable assumption. ONC201 represents a potentially useful alternative treatment option to Everolimus or PRRT, and the study has published results in peer-reviewed journals, indicating good scientific quality.
   Has Posted Results: YES (verified)
   Condition: Recurrent Neuroendocrine Tumor; Metastatic Neuroendocrine Tumor
   Intervention: ONC201
   Sponsor: Peter Anderson
   Start Date: 2017-08-02
   Completion Date: 2023-05-19
   Locations: Cleveland Clinic Pediatric and Taussig Cancer Institute, Case Comprehensive Cancer Center, United States
   URL: https://clinicaltrials.gov/study/NCT03034200
   Summary: The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocyt...
   Publications Found: 8
     1. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messa...
        PMID: 23390247
        Type: BACKGROUND
        Link: https://pubmed.ncbi.nlm.nih.gov/23390247/
     2. Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identif...
        PMID: 25927855
        Type: BACKGROUND
        Link: https://pubmed.ncbi.nlm.nih.gov/25927855/
     3. Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, B...
        PMID: 25681273
        Type: BACKGROUND
        Link: https://pubmed.ncbi.nlm.nih.gov/25681273/
----------------------------------------

9. Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
   NCT ID: NCT03972488
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study appears clinically relevant for the patient. The study focuses on GEP-NETs, which includes the patient's small bowel NET. The inclusion criteria specify Grade 2 and 3 tumors, which aligns with the patient's G2 diagnosis. While the patient's ECOG/KPS and biomarker data (Ki67) are missing, the study's criteria don't immediately exclude them, and the patient's history suggests they might meet the requirements. The intervention, Lutathera, is a PRRT therapy, directly addressing the clinical question of whether to pursue PRRT. The study is a Phase 3 trial with published results, indicating good scientific quality.
   Has Posted Results: YES (verified)
   Condition: Gastro-enteropancreatic Neuroendocrine Tumor
   Intervention: Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable
   Sponsor: Advanced Accelerator Applications
   Start Date: 2020-01-08
   Completion Date: 2027-10-29
   Locations: Yale Cancer Center, New Haven, United States; USF - H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States; University of Iowa Hospitals and Clinics - Oncology, Iowa City, United States
   URL: https://clinicaltrials.gov/study/NCT03972488
   Summary: The aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to tr...
   Publications Found: 2
     1. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto ...
        PMID: 38851203
        Type: RESULT
        Link: https://pubmed.ncbi.nlm.nih.gov/38851203/
     2. Jungels C, Deleporte A. State of the art and future directions in the systemic t...
        PMID: 33973550
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/33973550/
----------------------------------------

10. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
   NCT ID: NCT01524783
   Status: COMPLETED
   Phase: PHASE3
   Clinically Relevant: YES (Score: 1.0)
   Clinical Reasoning:
   This study is clinically relevant for the patient. The patient has a well-differentiated (G2) neuroendocrine tumor of the small intestine (GI origin), which aligns with the study's inclusion criteria. While the patient's prior therapies are not fully specified, the study allows patients previously treated with SSA, IFN, chemotherapy, or PRRT, provided they have progressed on prior treatment. The clinical question directly addresses one of the study arms (Everolimus), making the intervention potentially useful. Finally, the study is a Phase 3 trial with completed results and 5 publications, indicating good scientific quality.
   Has Posted Results: YES (verified)
   Condition: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
   Intervention: Everolimus; Placebo; Best suportive care (BSC)
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-03-30
   Completion Date: 2020-08-07
   Locations: University of California San Diego - Moores Cancer Center Regulatory, La Jolla, United States; Scripps Clinic Regulatory, La Jolla, United States; Cedars Sinai Medical Center SC, Los Angeles, United States
   URL: https://clinicaltrials.gov/study/NCT01524783
   Summary: The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of c...
   Publications Found: 5
     1. Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke ...
        PMID: 33560090
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/33560090/
     2. Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel...
        PMID: 29081664
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/29081664/
     3. Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassett...
        PMID: 29055056
        Type: DERIVED
        Link: https://pubmed.ncbi.nlm.nih.gov/29055056/
----------------------------------------